Advertisement

Gastrointestinal adverse events of semaglutide in patients with overweight or obesity

Published:August 16, 2022DOI:https://doi.org/10.1016/j.ejim.2022.08.015
      Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and is a well-established, safe, and effective treatment for type 2 diabetes mellitus (T2DM) with favorable effects on glycemic control, weight reduction and risk of major adverse cardiovascular events without increasing hypoglycemic incidence [
      • Shi FH
      • Li H
      • Cui M
      • Zhang ZL
      • Gu ZC
      • Liu XY
      Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
      ]. The efficacy of a higher dose of semaglutide in obese patients was evaluated in the Semaglutide Treatment Effect in People with Obesity (STEP) trials which reported clinically significant weight loss with the drug. Inn 2021, the Federal Drug Administration (FDA) approved semaglutide as adjunctive pharmacotherapy for obese patient populations to achieve weight loss [
      • Singh G
      • Krauthamer M
      • Bjalme-Evans M
      Wegovy (semaglutide): a new weight loss drug for chronic weight management.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shi FH
        • Li H
        • Cui M
        • Zhang ZL
        • Gu ZC
        • Liu XY
        Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
        Front Pharmacol. 2018; 9 (Jun 4): 576https://doi.org/10.3389/fphar.2018.00576
        • Singh G
        • Krauthamer M
        • Bjalme-Evans M
        Wegovy (semaglutide): a new weight loss drug for chronic weight management.
        J Investig Med. 2022; 70 (Jan): 5-13https://doi.org/10.1136/jim-2021-001952
        • Wilding JPH
        • Batterham RL
        • Calanna S
        • et al.
        Once-weekly semaglutide in adults with overweight or obesity.
        N Engl J Med. 2021; 384: 989-1002https://doi.org/10.1056/NEJMoa2032183
        • Sun F
        • Chai S
        • Yu K
        • Quan X
        • Yang Z
        • Wu S
        • Zhang Y
        • Ji L
        • Wang J
        • Shi L
        Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.
        Diabetes Technol Ther. 2015; 17 (Jan): 35-42https://doi.org/10.1089/dia.2014.0188
      1. Borner T, Workinger JL, Tinsley IC, Fortin SM, Stein LM, Chepurny OG, Holz GG, Wierzba AJ, Gryko D, Nexø E, Shaulson ED, Bamezai A, Da Silva VAR, De Jonghe BC, Hayes MR, Doyle RP. Corrination of a GLP-1 receptor agonist for glycemic control without emesis. cell rep. 2020 Jun 16;31(11):107768. https://doi.org/10.1016/j.celrep.2020.107768.

        • Lau DCW
        • Batterham RL
        • le Roux CW
        Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
        Expert Rev Clin Pharmacol. 2022; 15: 251-267https://doi.org/10.1080/17512433.2022.2070473
      2. ClinicalTrials.gov. STEP 5 trial. Available from: https://clinicaltrials.gov/ct2/show/NCT03693430 Accessed July 2022.

        • Ahrén B
        • Atkin SL
        • Charpentier G
        • et al.
        Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.
        Diabetes Obes Metab. 2018; 20: 2210-2219https://doi.org/10.1111/dom.13353